Selected Factors Associated with Metabolic Syndrome in Persons Living with HIV/AIDS Receiving Antiretroviral Therapy
Article Sidebar
Main Article Content
Abstract
Objective: The aims of this descriptive study were to determine prevalence of metabolic syndrome, and explore factors associated with metabolic syndrome in persons living with HIV/AIDS (PLHA) receiving antiretroviral therapy (ART) .
Methods: A sample of 424 PLHA receiving ART at SENA Hospital was recruited. Data collection consisted of personal data and health history, medical records, and ART records. The statistics for analyzing data included descriptive statistics frequency, percentage, mean, standard deviation, range, and odds ratio statistics to investigate factors associated with metabolic syndrome. Metabolic syndrome was defined by the National Cholesterol Education Program - Adult Treatment Panel III (NCEP-ATP III) .
Results: This study revealed that prevalence of metabolic syndrome was 28.10%. Significant risk factors associated with metabolic syndrome were female gender (OR=1.6; 95%CI=1.06-2.51; p=0.031), age ≥ 45 years (OR=1.6; 95 % CI =1.10-2.60; p =0.022), body mass Index ≥ 25 kg/m2 (OR=4.5; 95%CI=2.069-4.56; p= .000), CD4 > 400 cell/mm3 (OR=1.8; 95%CI=1.22-2.90; p=0.005), ART regimen with Didanosine, Stavudine, Efavirenz or Protease inhibitors (OR=1.9; 95%CI =1.15-3.39; p=0.018), and ART duration ≥12 months (OR=2.7; 95%CI=1.13-6.70; p =0.031) .
Conclusion: The results of this study showed that prevalence of metabolic Syndrome in PLHA receiving ART is relatively high compared to previous studies. Therefore, health providers should encourage PLHA receiving ART to have appropriate health promoting behaviors to prevent metabolic syndrome which can increase risk for cardiovascular disease.
Article Details
References
2. Nation Health Security Office. Number of HIV infected patients were received antiretroviral therapy and registered in national AIDS program of nation health security Office [Internet]. 2013 [update 2012 Nov 30; cited 2013 Dec 24]. Available form: https://www.napdlnhso.go.th/NAPWebReport/
3. Bureau of AIDS, Tuberculosis and STDs department of disease control. Thailand national guidelines on HIV/AIDS treatment and prevention 2017. Bangkok: Agricultural Cooperative Federation of Thailand; 2007. p. 33-137.
4. National Cholesterol Education Program Expert Panel. Executive summary of the third report of the national cholesterol education program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III) : Final report JAMA. 2001; 285: 2486-2497
5. Deerochanawong C. Metabolic syndrome [Internet]. 2006 [update 2006 Sep14; cited 2017 Jun 5] Available form: Chanchai htm.
6. Pie Y W, Hung CC, Liu W C, Hsich C Y, Sun H Y, Lu C L, et al. Metabolic syndrome among HIV-Infected Taiwanese patients in the era of highly active antiretroviral therapy: prevalence and associated factors. J Antimicrob Chemother. 2012; 67: 100-9.
7. Bergersen B M, Schumacher A, Sandvik l, Bruun JN, Birkeland K. Important differences in components of the metabolic syndrome between HIV – patient with and without highly active antiretroviral therapy and healthy controls. Scand J Infect Dis. 2006; 38: 682-9.
8. Estrada V, Martinez-Larrad MT, Gonnález- Sánchezb J, Villar N G, Zabena C, Fernandez C, et al. Lipodystrophy and metabolic syndrome in HIV – Infected patients treated with antiretroviral therapy. J Metab Clin Exp. 2006; 55: 940-5.
9. Kristin M, Edgar TO, Jessica G, Shao T, Warren S, William P, et al. Metabolic syndrome in HIVinfected patients form an urban, Mid-Western US outpatient population. J Clin Infect Dis. 2007; 44: 726-34.
10. Jacobson D l, Tang A M, Spiegelman D, Thomas A M, Skinner S L, Gobach SL, et al. Incidence of metabolic syndrome in a cohort of HIV- infected adults and prevalence relative to the US population (National Health and Nutrition Examination Survey) .J Acquir Immune Defic Syndr. 2006; 32: 298–302.
11. Aekplalakorn W. The fourth Thai national health examination survey B.E.2552.4thed. Bangkok: The Graphic System Limited; 2009.p.166-167.
12. Plubboodee P. Prevalence of metabolic syndrome in HIV Infected patients Treated with Non - nucleoside reverse transcriptase Inhibitors (NNRTIs) based highly active antiretroviral therapy [dissertation]. University Prince of Songkla; 2011. 83p.
13. Alvarez C, Salazar R, Galindez J, Rangel F, Castaneda M.L, Lopardo G, et al. Metabolic syndrome in HIV - infected patients receiving antiretroviral therapy in Latin America. Braz J Infect Dis. 2010; 14: 256-63.
14. Aubune M. Lipodystrophy and metabolic syndrome in Romanian HIV-Infected adult. J Int AIDS Soc. 2010; 13: 71.
15. Homkham N. Changes of fat levels within 2 years of follow up in Thai patients HIV infection after antiretroviral therapy [abstract]. In: National Symposium on AIDS 13; 2011 Mach 29-31; Impact Mungthongthanee Bangkok, Thailand; 2011. p. 126.
16. Sobieszczyk ME, Hoover DR, Anastos K, Muligan K, Tan T, Shi Q, et al. Prevalence and predictors of metabolic syndrome among HIV-Infected and HIV- uninfected woman in the women's Interagency HIV study. J Acquir Immune Defic Syndr. 2008; 48: 272- 80.
17. Samaras K, Wand H, Law M, Emery S, Cooper D, Carr A. Prevalence of metabolic syndrome in HIV- infected patients receiving highly active antiretroviral therapy using Internationnal diabetes foundation and adult treatment panel III criteria: associations with insulin resistance, disturbed body fat compartmentalization, elevated C- reactive protein, and corrected hypoadiponectinemia. Diabetes Care.2007; 30: 113-9.
18. Jerico C, Gimino J L, Knobel H, Saballs P, Montero M, Lopez- Colomes J l, et al. Metabolic syndrom among HIV– Infected patients. Diabetes Care.2005; 28: 144-9.
19. Jantarapakdee J. The prevalence of metabolic syndrome in HIV- infected Thai people in the project MTCT- Plus [abstract]. In: National Symposium on AIDS 13; 2011 Mach 29-31; Impact Mungthongthanee Bangkok, Thailand; p. 131.
20. Sermsak P. Prevalence and risk factor metabolic syndrome of employees who work in shifts in an electric component factory in Nakhon Ratchasima. Nursing Journal of the Ministry of Public Health. 2014; 25: 157-65.
21. Ratanahirunsuk C, Pakdevong N, Binhosen V. Association between health behaviors and metabolic syndrome of the employee in one private hospital association of private higher education Institutions of Thailand under the patronage of her royal highness princess Maha Chakri Sirinthorn. 2015; 4: 64-74
22. Kiertiburanakul S. Side effect of antiretroviral drugs management. In: Kiertiburanakul S, editor. Ambulatory care of HIV– infected patients. Bangkok: Beyond Enterprise Price Limited; 2014.p. 108-37.
23. Boonchong N, Dawvongyad N, Moolasarn S. Dyslipidemia status in HIV- infected/AIDS patients receiving an antiretroviral agent (GPO-VIRS). Thai Pharmaceutical and Health Science Journal. 2008; 3: 19-29.